Tenax Therapeutics is trading 11.36% up at $2.21 as investor interest increased following its September 9, 2026 presentation at the Cantor Global Healthcare Conference.
- CEO Chris Giordano presented updated Phase 3 LEVEL trial results for TNX-103, including clinically meaningful gains in a patient subgroup and a revised registrational strategy.
- ADAR1 Capital Management recently disclosed additional purchases of 900,000 shares on September 3, 2026.